Evidence map›Paper›PMID 23881112›Full record

ArticleAnnals of biomedical engineering2014

PEG-maleimide hydrogels for protein and cell delivery in regenerative medicine.

Andrés J García

Abstract read
In one paragraph

Article in Annals of biomedical engineering, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Engineering hydrogels with homogeneous mechanical properties for controlling stem cell lineage specification.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  11. Review
  12. Article
  13. Review
  14. Large three-dimensional cell constructs for tissue engineering.Science and technology of advanced materials · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Andrés J GarcíaWoodruff School of Mechanical Engineering, Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA, andres.garcia@me.gatech.edu.

Funding

Cell therapy for diabetic peripheral neurovascular complicationsDP3DK094346 · NIDDK · EMORY UNIVERSITY · PI CHENG, XIAODONG, YOON, YOUNG-SUP · 2011 to 2011
$6.1M
Hydrogels for hMSC delivery & engraftmentR01AR062368 · NIAMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2012 to 2022
$3.5M
Osseo-reparative, integrin-specific materialsR01AR062920 · NIAMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2012 to 2021
$3.2M
NIAMS NIH HHS R01 AR062368NIAMS NIH HHS R01 AR062920NIDDK NIH HHS DP3 DK094346
6 · The paper itself

Abstract

Protein- and cell-based therapies represent highly promising strategies for regenerative medicine, immunotherapy, and oncology. However, these therapies are significantly limited by delivery considerations, particularly in terms of protein stability and dosing kinetics as well as cell survival, engraftment, and function. Hydrogels represent versatile and robust delivery vehicles for proteins and cells due to their high water content that retains protein biological activity, high cytocompatibility and minimal adverse host reactions, flexibility and tunability in terms of chemistry, structure, and polymerization format, ability to incorporate various biomolecules to convey biofunctionality, and opportunity for minimally invasive delivery as injectable carriers. This review highlights recent progress in the engineering of poly(ethylene glycol) hydrogels cross-linked using maleimide reactive groups for protein and cell delivery.

Indexed as

HydrogelsAnimalsDrug Delivery SystemsMaleimidesMicePolyethylene GlycolsRegenerative MedicineHydrogelsmaleimideMaleimidesPolyethylene Glycols

Identifiers

PMID23881112
PMCPMC3875614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.